220 Results for "

complementation

" in MedChemExpress (MCE) Product Catalog:
Products (220)

220 Results for "complementation" in MCE Product Catalog:

Cat. No.: HY-134222A
CAS No.: 16354-58-8
Purity:  ≥98.0%
Synonyms: N-Acetyl-L-serine
N-Acetylserine (N-Acetyl-L-serine) is a complement pathway modulator targeting activated third complement protein (C3b) and an amino-terminal residue (an N-terminal acetylation modification group). N-Acetylserine reacts with the exposed thioester group of C3b via its hydroxyl group, thereby blocking the covalent binding of glycerol to this thioester group. N-Acetylserine widely exists in soluble proteins of mammalian cells (accounting for approximately 80% of such proteins). N-Acetylserine has a blocking property that prevents direct Edman sequencing of proteins; deblocking is achievable through trifluoroacetic acid-catalyzed N→O acetyl migration followed by β-elimination. N-Acetylserine is suitable for sequencing of proteins with N-terminal acetylserine modification .
loading...
    loading...
Cat. No.: HY-P991127
CAS No.: 2922766-89-8
Synonyms: DNTH103

Target:  

Complement System

연구분야:  

Inflammation/Immunology

Claseprubart (DNTH103) is an inhibitor targeting C1s of the complement system and an inhibitor of the C1 component of the complement cascade. Claseprubart is in phase 2 clinical evaluation. Claseprubart has application potential in research related to multifocal motor neuropathy and generalized myasthenia gravis .
loading...
    loading...
Cat. No.: HY-128570
CAS No.: 1646682-14-5
Purity:  99.24%
Target:  

Complement System

연구분야:  

Inflammation/Immunology

FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC50 of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system. FD-IN-1 also inhibits factor XIa (FXIa) and Tryptase β2 with IC50s of 7.7 and 6.5 µM, respectively .
loading...
    loading...
Cat. No.: HY-P99050
CAS No.: 2049079-64-1
Synonyms: BIVV009; IPN-009; TNT009

Target:  

Complement System

연구분야:  

Endocrinology

Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome .
loading...
    loading...
Cat. No.: HY-P99520
CAS No.: 2250440-41-4
Synonyms: CaCP-29, IFX-1
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .
loading...
    loading...
Cat. No.: HY-P99365
CAS No.: 1803171-55-2
Synonyms: ALXN1210

Target:  

Complement System

연구분야:  

Metabolic Disease

Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
loading...
    loading...
Cat. No.: HY-P990952
CAS No.: 2527079-60-1
Synonyms: OMS906
Zaltenibart (OMS906) is an IgG4 humanized monoclonal antibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria .
loading...
    loading...
Cat. No.: HY-NP0194A
C1q Protein (mouse) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (mouse) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (mouse) can be used for the research of mutiple disease .
loading...
    loading...
Cat. No.: HY-P99358
CAS No.: 1662664-56-3
Synonyms: GSK 2398852; Anti-Serum Amyloid P/SAP Reference Antibody (dezamizumab)

Target:  

Complement System

연구분야:  

Inflammation/Immunology

Dezamizumab (GSK 2398852) is a fully humanized clonal IgG1 antibody against serum amyloid P component (SAP) with complement activation and amyloid clearance-inducing activities. Dezamizumab binds to SAP associated with amyloid deposits to form complexes that activate complement and mediate phagocytic clearance, triggering activation of the classical complement pathway. Dezamizumab can be used for the research of systemic amyloidosis .
loading...
    loading...
Cat. No.: HY-145720
CAS No.: 1639264-46-2
Synonyms: ALN-CC5
Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .
loading...
    loading...
Cat. No.: HY-P990091
CAS No.: 2756228-76-7
Synonyms: SAR 445088
Riliprubart (SAR 445088) is a selective anti-C1s humanized IgG4 monoclonal antibody with mutations that enhance its binding to the neonatal Fc receptor. Riliprubart blocks activation of the classical complement pathway, prevents the formation of the C3 convertase C4b2a, and inhibits complement-mediated hemolytic activity. Riliprubart can be used in research related to classical complement-mediated diseases, cold agglutinin disease, and chronic inflammatory demyelinating polyneuropathy. For the isotype control of Riliprubart, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
loading...
    loading...
Cat. No.: HY-148457
CAS No.: 1613641-69-2
Synonyms: Izervay
Avacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA .
loading...
    loading...
Cat. No.: HY-P99450
CAS No.: 2226393-85-5
Synonyms: IPH 5401; Anti-C5aR1 mAb

Target:  

Complement System

연구분야:  

Inflammation/Immunology Cancer

Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
loading...
    loading...
Cat. No.: HY-P99638
CAS No.: 2456407-94-4
Synonyms: ALXN-1720

Target:  

Complement System

연구분야:  

Inflammation/Immunology

Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis .
loading...
    loading...
Cat. No.: HY-P990025
CAS No.: 2579031-19-7
Synonyms: ARGX-117

Target:  

Complement System

연구분야:  

Inflammation/Immunology

Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .
loading...
    loading...
Cat. No.: HY-P1823
CAS No.: 147516-85-6
C-Reactive Protein (CRP) is an anti-pneumococcal plasma protein that can serve as an inflammatory marker. C-Reactive protein can protect mice from pneumococcal infection by activating complement. C-Reactive protein can inhibit the activation of caspase-3/9 through the CD64/AKT/mTOR pathway, thereby promoting chemotherapy resistance in mice with tongue squamous cell carcinoma .
loading...
    loading...
Cat. No.: HY-P99786
CAS No.: 2096328-94-6
Synonyms: REGN3918

Target:  

Complement System

연구분야:  

Metabolic Disease

Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
loading...
    loading...
Cat. No.: HY-148370A
CAS No.: 2272983-11-4
Purity:  93.90%
Synonyms: IONIS-FB-LRx sodium; RG6299 sodium; ISIS 696844 sodium
Target:  

Complement System

연구분야:  

Others

Sefaxersen sodium is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). Sefaxersen sodium effectively reduces circulating levels of CFB, and can be used for geographic atrophy (GA) research .
loading...
    loading...
Cat. No.: HY-148370
CAS No.: 2272975-74-1
Synonyms: IONIS-FB-LRx; RG6299; ISIS 696844
Target:  

Complement System

연구분야:  

Others

Sefaxersen (IONIS-FB-LRx) is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). Sefaxersen effectively reduces circulating levels of CFB. Sefaxersen can be used for geographic atrophy (GA) research .
loading...
    loading...
Cat. No.: HY-P99298
CAS No.: 1278466-20-8
Synonyms: RG 7417; TNX 234; Anti-CFD Recombinant Antibody

Target:  

Complement System

연구분야:  

Inflammation/Immunology

Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .
loading...
    loading...